PHIO Stock Risk & Deep Value Analysis

Phio Pharmaceuticals Corp

Healthcare • Biotechnology

DVR Score

0.6

out of 10

Distressed

The Bottom Line on PHIO

We analyzed Phio Pharmaceuticals Corp using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PHIO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Feb 16, 2026•Run Fresh Analysis →

📈PHIO Performance Overview3yr weekly

📊

Unlock PHIO Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

PHIO Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

About Phio Pharmaceuticals Corp (PHIO)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$13.08M

PHIO Deep Value Analysis

Phio Pharmaceuticals continues to present an extremely high-risk, high-reward profile for 10x growth within the next 3-5 years. Its focus on the large immuno-oncology market with the sd-rxRNA platform and lead candidate PH-762 offers theoretical upside upon definitive clinical success. Since the last analysis 12 days ago, the market capitalization has doubled from $10M to $20M, reflecting increased speculative interest. However, this market movement does not fundamentally alter the company's precarious financial health, ultra-low cash runway, and the binary nature of early-stage biotech development. Significant future dilution remains highly probable, and without groundbreaking positive clinical data or a substantial strategic partnership, a sustainable 10x return remains exceptionally challenging.

PHIO Red Flags & Warning Signs

Premium

⚠
Negative or inconclusive PH-762 clinical trial results
⚠
Significant shareholder dilution via equity offerings
⚠
Inability to secure sufficient future funding

Unlock PHIO Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

PHIO Financial Health Metrics

Market Cap

$13.08M

PHIO Competitive Moat Analysis

Premium

Moat Rating

None

Moat Trend

Stable

Moat Sources

1 Identified

Intangible Assets/IP

Currently, the moat is nascent, based solely on its proprietary sd-rxRNA platform and associated intellectual property. Its durability is entirely contingent on clinical success and the ability to differentiate from numerous other immuno-oncology approaches.

PHIO Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

PHIO Catalysts & Growth Drivers

Near-Term (0-6 months)

•PH-762 Phase 1/2a clinical data updates (Estimated Q2/Q3 2026)
•New financing round announcements

Medium-Term (6-18 months)

•Strategic partnership or licensing deal for sd-rxRNA platform
•Expansion of pipeline candidates into clinical trials

Long-Term (18+ months)

•PH-762 advancement to pivotal Phase 2/3 trials
•Broad validation of sd-rxRNA platform across multiple indications

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

PHIO Bull Case: What Could Go Right

✓
Definitive positive clinical trial results for PH-762
✓
Announcement of a strategic partnership or non-dilutive funding
✓
Extension of cash runway to beyond 18 months without excessive dilution

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on PHIO

Create a free account to set price alerts and get notified on Telegram when PHIO hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Phio Pharmaceuticals Corp (PHIO)?

As of February 16, 2026, Phio Pharmaceuticals Corp has a DVR Score of 0.6 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Phio Pharmaceuticals Corp?

Phio Pharmaceuticals Corp's market capitalization is approximately $13.1M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does Phio Pharmaceuticals Corp use?

PHIO is the ticker symbol for Phio Pharmaceuticals Corp. The company trades on the NCM.

What is the risk level for PHIO stock?

Our analysis rates Phio Pharmaceuticals Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the PHIO DVR analysis updated?

Our AI-powered analysis of Phio Pharmaceuticals Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 16, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.